Diabetic Retinopathy – Epidemiology – Emerging Markets

Clarivate Epidemiology’s coverage of diabetic retinopathy (DR) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of DR for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the remaining countries covered in this report.

Clarivate Epidemiology’s DR forecast will answer the following questions:

• Of all people with DR, how many in each of the major mature pharmaceutical markets are diagnosed?
• Of all people with DR, how many in each of the major mature pharmaceutical markets are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of DR over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.

Clarivate Epidemiology provides at least 10 years of forecast data for the following DR patient populations:

• Total prevalent cases of DR.
• Total prevalent cases of proliferative DR.
• Total prevalent cases of nonproliferative DR.
• Total prevalent cases of nonproliferative DR by severity subtype.
• Dx prevalent cases of severe nonproliferative DR.
• Dx prevalent cases of proliferative DR.
• Drug-treated prevalent cases of severe nonproliferative DR.
• Drug-treated prevalent cases of proliferative DR.

Note: Coverage may vary by country and region.